The prognostic value of androgen receptors in breast cancer subtypes.

Autor: Kraby MR; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Valla M; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway., Opdahl S; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway., Haugen OA; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Sawicka JE; Department of Clinical Pharmacology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway., Engstrøm MJ; Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Breast and Endocrine Surgery, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway., Bofin AM; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. anna.bofin@ntnu.no.; Department of Clinical and Molecular Medicine, The Laboratory Centre, Norwegian University of Science and Technology, Erling Skjalgssons gate 1, 7030, Trondheim, Norway. anna.bofin@ntnu.no.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2018 Nov; Vol. 172 (2), pp. 283-296. Date of Electronic Publication: 2018 Aug 14.
DOI: 10.1007/s10549-018-4904-x
Abstrakt: Purpose: Androgen receptor (AR) expression is frequent in breast cancer and has been associated with good prognosis in several studies. The present study investigates AR-expression in relation to molecular subtypes, clinicopathological features and prognosis in 1297 primary tumours and 336 paired axillary lymph node metastases (LNM) from two cohorts of Norwegian patients.
Methods: Immunohistochemistry for AR was performed on tumours previously reclassified into molecular subtypes using immunohistochemistry and in situ hybridisation. Associations between AR-expression and clinical features were studied using Chi-square tests. Cumulative incidence of breast cancer death and Cox regression analyses were used to assess prognosis.
Results: AR-positivity was found in 78.0% of all cases, 84.9% of luminal and 45.1% of non-luminal tumours. The highest proportion of AR-positivity was found in Luminal B tumours, and the lowest in the Basal phenotype. Discordance in AR-status between primary tumours and lymph node metastases was observed in 21.4% of cases. A switch from AR - primary tumour to AR + lymph node metastasis was seen in 60/72 discrepant cases. AR-expression in primary tumours was an independent and favourable prognostic marker (HR 0.70, 95% CI 0.55-0.90), particularly in the Luminal A subtype, and in grade 3 tumours.
Conclusions: AR is an independent predictor of good prognosis in BC, particularly in grade 3 and Luminal A tumours. Discordant AR-expression between primary tumour and LNM was observed in 21.4% of cases and most often there was a switch from AR - primary tumour to AR + axillary LNM.
Databáze: MEDLINE
Externí odkaz: